Scholarlink

<p>The clinical manifestations of intrahepatic cholangiocarcinoma (ICC) are non-specific, and few patients qualify for surgical resection at diagnosis, thus limiting treatment options. Anticancer peptides (ACPs) exhibit potent tumour inhibition, minimal side effects, easy modification, and low production costs, making them promising for clinical use. Simultaneously, the development of patient-derived three-dimensional organoids as a novel disease model has enabled the replication of the structure and heterogeneity of solid tumours. These organoids provide valuable tools for understanding disease mechanisms, conducting drug sensitivity tests, and developing targeted therapies. However, ACPs’ effect on ICC organoids remain unclear. Therefore, this study aims to explore the potential of ACPs in treating ICC using patient-derived organoids (PDOs). We designed and synthesised a series of ACPs sequences and applied them to PDOs model. The organoid model exhibits histological and genomic characteristics similar to those of maternal tumours. Drug sensitivity revealed that ACPs affected the growth of tumour cells and exerted anticancer effects through direct membrane disruption and indirect induction of apoptosis. In this study, organoids can be used as an in vitro model to evaluate the therapeutic response of ACPs and offer novel insight for the study of ICC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Application and mechanism of anticancer peptides in organoid models of intrahepatic cholangiocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月2日

查看全文
  • Xuekai Hu,
  • Yue Zhang,
  • Yanchen Li,
  • Qiuxia Zheng,
  • Haixia Zhao,
  • Yun Zhang,
  • Jingman Ni,
  • Jia Yao

摘要

The clinical manifestations of intrahepatic cholangiocarcinoma (ICC) are non-specific, and few patients qualify for surgical resection at diagnosis, thus limiting treatment options. Anticancer peptides (ACPs) exhibit potent tumour inhibition, minimal side effects, easy modification, and low production costs, making them promising for clinical use. Simultaneously, the development of patient-derived three-dimensional organoids as a novel disease model has enabled the replication of the structure and heterogeneity of solid tumours. These organoids provide valuable tools for understanding disease mechanisms, conducting drug sensitivity tests, and developing targeted therapies. However, ACPs’ effect on ICC organoids remain unclear. Therefore, this study aims to explore the potential of ACPs in treating ICC using patient-derived organoids (PDOs). We designed and synthesised a series of ACPs sequences and applied them to PDOs model. The organoid model exhibits histological and genomic characteristics similar to those of maternal tumours. Drug sensitivity revealed that ACPs affected the growth of tumour cells and exerted anticancer effects through direct membrane disruption and indirect induction of apoptosis. In this study, organoids can be used as an in vitro model to evaluate the therapeutic response of ACPs and offer novel insight for the study of ICC.